DEMECAN applies for an increase in production quantities of medical cannabis and calls for equal competition conditions for domestic producers.

Ebersbach, Germany, May 2nd, 2023 Last week, the Saxon company DEMECAN officially filed an application with the Federal Institute for Drugs and Medical Devices (BfArM) to increase the production quantities of medical cannabis in Germany. With the aim of creating equal competition conditions for domestic producers, DEMECAN is calling for an increase in production quantities and an end to the discrimination against German producers.

"There is unequal treatment between German and foreign producers of medical cannabis in Germany," says Dr. Constantin von der Groeben, Managing Director of DEMECAN. "While foreign producers can produce unlimited quantities and import them to Germany, domestic producers such as DEMECAN are only allowed to produce 990 kg. This unequal treatment must now be ended!" adds Dr. von der Groeben.

DEMECAN advocates for higher production of medical cannabis in Germany to ensure the supply of medical cannabis to patients, ensure quality locally, and strengthen the German economy. The company is willing to bear the economic risk for the additional quantities itself and suggests that additional quantities of medical cannabis be awarded through an open-house procedure.

DEMECAN's application follows information from the BfArM from an IFG application for controlling foreign producers exporting medical cannabis to Germany. These revealed that foreign producers are subject to neither quantity nor price restrictions. A small inquiry from the Bundestag fraction DIE LINKE in November 2022 also revealed that permits have now been issued for the import of 78,672.20 kg of dried cannabis flowers, including from Lesotho, Jamaica, and Canada, among others. Permits without quantity restrictions were also granted for North Macedonia.

DEMECAN sees its application as an opportunity to restore competition equilibrium in the industry and strengthen the domestic market. The company remains confident that its application will be positively answered and looks forward to continuing to produce high-quality medical cannabis in Germany.

About DEMECAN

DEMECAN is the only independent German company that covers the entire value chain for medical cannabis – from cultivation to processing and storage to distribution to pharmacies. The company was founded in 2017 by Dr. Adrian Fischer, Dr. Cornelius Maurer and Dr. Constantin von der Groeben with the aim of guaranteeing patients access to medical cannabis in “Made in Germany” quality. In May 2019, DEMECAN was awarded a state contract by the Federal Institute for Drugs and Medical Devices (BfArM) as the only independent German company to cultivate medical cannabis in Germany. Cultivation and further processing are carried out according to the highest pharmaceutical standards (EU-GMP) at the company’s facility near Dresden. As a pharmaceutical wholesaler, DEMECAN works with cannabis producers worldwide and imports medical cannabis that meets its own high-quality standards. The DEMECAN Group is a member of the Federal Association of Pharmaceutical Cannabinoid Companies (BPC), Cannabis Business Industry Association e.V. (BvCW) and a supporting member of the Association of Pharmacies Supplying Cannabis (VCA e.V.).

Further Information: www.demecan.de
Press contact: press@demecan.de

DEMECAN successfully closes its funding round and collects a total of EUR 15m in 2022

Berlin/Dresden, Germany, December 19, 2022 – DEMECAN, the only independent vertically-integrated cannabis company in Germany, successfully closes its current funding round. The company raised capital totaling EUR 15 million in 2022, consisting of loans and equity financing.

The funding will finance the further expansion of the company, including to increase production capacity at the facility in Ebersbach near Dresden/Saxony. Here, cannabis services, such as the processing of cannabis flower, are also offered to third parties. In addition, the expansion is part of the company’s preparations for the upcoming legalization of cannabis for recreational use. However, the company also remains active in the field of medical cannabis and is pushing ahead with research and development. Recently, the company’s cell culture laboratory at the Ebersbach site produced its first plants from tissue culture.

The investment in this funding round comes from private and institutional investors. Both existing shareholders and new investors are supporting the company in its further entrepreneurial development. Among others, Mittelständische Beteiligungsgesellschaft Sachsen (MBG) and the Swedish dedicated Cannabis fund ENEXIS AB are joining existing shareholders, including the Frankfurt-based funds Futury Growth and Futury Venture as well as btov’s Private Investor Network as investors in DEMECAN, thus participating in one of Saxony's leading start-ups’ expansion course.

"DEMECAN pursues the mission of supplying the German market with high-quality medical cannabis and contributing to the security of supply for patients. We also have the legalization of recreational cannabis in mind. The value chain of cannabis will probably have to be fully mapped in Germany. This will bring new challenges but great opportunities for us as a vertically integrated cannabis company and we are already preparing today for it" comments Jörg Sellmann, member of DEMECAN’s executive board.

MBG sees the investment in DEMECAN as an opportunity to foster a still young and future-proved German market from Saxony. “Our funding for DEMECAN makes sense in several ways. We have been following the development of the Ebersbach production facility from the very beginning. Now is the right time for us to invest. DEMECAN has exciting times ahead, as markets develop further. The demand for cannabis will keep increasing in the near future. The number of Cannabis patients is growing, and the legalization of recreational cannabis is on the way", says Markus H. Michalow, Managing Director of MBG. "We are proud to play a part in the further development of this forward-looking company here in Saxony", he continued.

About DEMECAN

DEMECAN is the only independent German company that covers the entire value chain for medical cannabis - from cultivation to processing and storage to distribution to pharmacies. The company was founded in 2017 by Dr. Adrian Fischer, Dr. Cornelius Maurer and Dr. Constantin von der Groeben with the aim of guaranteeing patients access to medical cannabis in "Made in Germany" quality. In May 2019, DEMECAN was awarded a state contract by the Federal Institute for Drugs and Medical Devices (BfArM) as the only independent German company to cultivate medical cannabis in Germany. Cultivation and further processing are carried out according to the highest pharmaceutical standards (EU-GMP) at the company's facility near Dresden. As a pharmaceutical wholesaler, DEMECAN works with cannabis producers worldwide and imports medical cannabis that meets its own high-quality standards. The DEMECAN Group is a member of the Federal Association of Pharmaceutical Cannabinoid Companies (BPC) and a supporting member of the Association of Pharmacies Supplying Cannabis (VCA e.V.).

Further Information: www.demecan.de
Press contact: press@demecan.de

DEMECAN receives state subsidies and strengthens its management with Jörg Sellmann

Berlin/Dresden, September 2021 DEMECAN, the only independent German producer of medical cannabis, will receive substantial state subsidies worth several million Euros.

An application for the “Gemeinschaftsaufgabe ‘Verbesserung der regionalen Wirtschaftsstruktur’” (GRW) subsidies, which had been submitted to the Sächsische Aufbaubank for the expansion of the production plant near Dresden, was recently approved. The focus of the subsidies program lies in supporting the regional industry. DEMECAN’s investments in the construction of the cannabis production facility will receive a 30% subsidy from the Sächsische Aufbaubank. This measure is financed with tax funds based on the budget adopted by the Parliament of Saxony.

"We are thrilled about the support of the Sächsische Aufbaubank. For the further expansion of our production site near Dresden, the subsidies are great news, and it confirms our decision to have chosen Saxony as the location for our production," says Dr. Constantin von der Groeben, Managing Director and co-founder of DEMECAN.

DEMECAN has also recently strengthened its management team with a new appointment. Jörg Sellmann has joined the management board and will lead the financial department as managing director.

After concluding his training as a banker at Deutsche Bank, Jörg Sellmann completed his studies in business administration at the Westfälische Wilhelms University in Münster. Prior to joining DEMECAN’s management board, he worked in investment banking for several years before holding the position of Global Head of M&A at the chemical group Degussa AG in Düsseldorf. Subsequently, Jörg Sellmann worked as Senior Director at the European private equity fund EQT in Munich. After that, he successfully founded start-ups in various sectors, has since been active as a business angel, and is also a shareholder of DEMECAN. 

The new Managing Director, Jörg Sellmann, is excited about the new challenges at DEMECAN: "I am very pleased to contribute my professional experience to the up-and-coming start-up DEMECAN and to inspire new momentum with my expertise. Medical cannabis is a fantastic growth market and DEMECAN has established itself as the leading German manufacturer with a promising outlook on Europe and the rest of the world."

About DEMECAN
DEMECAN is the only independent German company that covers the entire production chain for medical cannabis - from cultivation, processing, and storage to distribution to pharmacies. The company was founded in 2017 by Dr. Adrian Fischer, Dr. Cornelius Maurer and Dr. Constantin von der Groeben with the aim of guaranteeing patients access to medical cannabis with "Made in Germany" quality. The Federal Institute for Drugs and Medical Devices (BfArM) awarded DEMECAN the contract to grow and process medical cannabis in May 2019. Cultivation and further processing are carried out in accordance with the highest pharmaceutical standards at the facility near Dresden. As a pharmaceutical wholesaler, DEMECAN cooperates with cannabis producers worldwide and imports medical cannabis that meets its own high-quality standards. The DEMECAN Group is a member of the Federal Association of pharmaceutical Cannabinoid Companies (BPC) and a supporting member of the Association of Cannabis Supplying Pharmacies (VCA e.V.).

Further Information: www.demecan.de
Presse contact: press@demecan.de

DEMECAN expands and diversifies its network of international suppliers of cannabis

Berlin/Dresden, June 09, 2022 – DEMECAN has signed major supply agreements for medicinal cannabis flowers with Little Green Pharma (Denmark), Safricanna (South Africa), and Atlas Growers (Canada). Over the next few years, DEMECAN will be supplied exclusively with at least 6 different medical cannabis flowers from these three suppliers. Deliveries will begin this year, subject to regulatory and licensing requirements. The combined amount will be over 2.2 tons of dried cannabis flower in the first year of delivery alone.

DEMECAN is Germany’s leading medical cannabis company and the only independent German company to have been awarded the contract by the Federal Institute for Drugs and Medical Devices (BfArM) to grow, process and distribute medical cannabis in Germany. In April, DEMECAN delivered for the first time from its domestically cultivated cannabis flowers directly to the BfArM. To guarantee the security of supply for patients in Germany, DEMECAN also works as a pharmaceutical wholesaler with cannabis producers worldwide and imports medical cannabis.

By expanding its supplier network, DEMECAN will continue to lead the way in providing patients with the highest quality medical cannabis products and at the same time diversifies its supplier network for the upcoming legalization of recreational cannabis in Germany. This allows DEMECAN to further consolidate its position as the go-to company for medical cannabis and at the same time provides a possible advantage for the future recreational cannabis market in Germany.

About DEMECAN

DEMECAN is the only independent German company that covers the entire value chain for medical cannabis - from cultivation to processing and storage to distribution to pharmacies. The company was founded in 2017 by Dr. Adrian Fischer, Dr. Cornelius Maurer and Dr. Constantin von der Groeben with the aim of guaranteeing patients access to medical cannabis in "Made in Germany" quality. In May 2019, DEMECAN was awarded a state contract by the Federal Institute for Drugs and Medical Devices (BfArM) as the only independent German company to cultivate medical cannabis in Germany. Cultivation and further processing are carried out according to the highest pharmaceutical standards (EU-GMP) at the company's facility near Dresden. As a pharmaceutical wholesaler, DEMECAN works with cannabis producers worldwide and imports medical cannabis that meets its own high-quality standards. The DEMECAN Group is a member of the Federal Association of Pharmaceutical Cannabinoid Companies (BPC) and a supporting member of the Association of Pharmacies Supplying Cannabis (VCA e.V.).

Further Information: www.demecan.de
Press contact: press@demecan.de

DEMECAN launches medicinal cannabis flower with cultivar Sour Kush

Berlin/Dresden, May 09, 2022 – DEMECAN, the only independent German producer of medicinal cannabis, is celebrating the launch of its supply agreement with Northern Green Canada with the launch of its new indica-dominant medicinal cannabis flower. With the expansion of the product portfolio, DEMECAN is helping to further improve patient care in Germany and is further expanding its position in the German cannabis market.

DEMECAN introduces the first cannabis flower from Northern Green Canada: it is an Indica-dominant cannabis flower with high THC levels and the cultivar Sour Kush (OG Kush x Sour Diesel), a multi-award-winning cross between Sour Diesel strains and OG Kush. 

New cannabis flower in "Made in Germany" quality

By concluding the supply agreement with Northern Green Canada Inc., DEMECAN will be able to supply pharmacies and patients with the high-quality cannabis from its EUGMP-certified partner in the future. Cultivation in an indoor facility ensures the highest quality standards, especially in terms of consistent concentrations of active ingredients, rich terpene abundance, and an extremely low microbiological load. This means that radiation is not necessary. In order to ensure a particularly high level of quality, DEMECAN also carries out the final processing in Germany.

Interested doctors and pharmacies can find further information in the specialist area of ​​the DEMECAN website, via DEMECAN customer service or the Medical Affairs Team. Patients can contact their doctor or pharmacy for information.

About DEMECAN

DEMECAN is the only independent German company that covers the entire value chain for medical cannabis - from cultivation to processing and storage to distribution to pharmacies. The company was founded in 2017 by Dr. Adrian Fischer, Dr. Cornelius Maurer and Dr. Constantin von der Groeben with the aim of guaranteeing patients access to medical cannabis in "Made in Germany" quality. In May 2019, DEMECAN was awarded a state contract by the Federal Institute for Drugs and Medical Devices (BfArM) as the only independent German company to cultivate and distribute medical cannabis in Germany. Cultivation and further processing are carried out according to the highest pharmaceutical standards (EU-GMP) at the company's facility near Dresden. As a pharmaceutical wholesaler, DEMECAN works with cannabis producers worldwide and imports medical cannabis that meets its own high quality standards. The DEMECAN Group is a member of the Federal Association of Pharmaceutical Cannabinoid Companies (BPC) and a supporting member of the Association of Pharmacies Supplying Cannabis (VCA e.V.).

Further Information: www.demecan.de
Press contact: press@demecan.de

About Northern Green Canada

Northern Green Canada Inc. is the first privately held EU GMP-certified cannabis producer focused on providing cannabis medicines for a better quality of life. Their experienced team of experts operates in an EU GMP-certified, 2500 m2 (27000 square foot) indoor growing and processing facility with a 4275 m2 (46000 square foot) expansion capability. The company is growing their extraction capacity to produce oils and is working with respected partners on treatment-based cannabis medications.

Find more information at: www.northerngreencanada.com

DEMECAN delivers first medical cannabis from its own German facility

Berlin/Dresden, April 20, 2022 – DEMECAN, the only independent German producer of medical cannabis, has made the first cannabis flowers available for collection by the German Federal Institute for Drugs and Medical Devices (BfArM). With this, DEMECAN ensures a constant supply of high-quality medical cannabis from German cultivation and increases the independence from imports in the supply of medicinal products.

DEMECAN is the only independent German cannabis producer supplying patients in Germany with cannabis flowers from its own EU-DEMECAN has established itself as the only independent producer of medical cannabis and leading wholesaler in Germany. 2500 cannabis plants are now growing in its own flower rooms in Saxony. In 2022, over 300 kg of high-quality cannabis flowers have already been harvested, dried and packaged to date. Over 100 kg of these will be made available for collection on April 20 by the federal cannabis agency and for distribution to pharmacies.

DEMECAN's first harvest for pharmacies in Germany.

DEMECAN was the only independent German company to be awarded a contract by the BfArM to produce cannabis flowers in Germany. In an elaborate selection process, DEMECAN chose an indica-dominant strain based on the cultivar OG Kush with a high THC content. The phenotype chosen for production was carefully selected by DEMECAN from over 250 plants.

DEMECAN has already been able to produce about half of the quantity ordered annually by the BfArM. Up to 660 kg of this variety are delivered from Saxony per year. In the future, DEMECAN could even produce much larger quantities of high quality cannabis than previously allocated by the BfArM. Since March, another variety (Typ 2 DEMECAN) is also in cultivation. DEMECAN will announce more details about this variety at the upcoming delivery.

Knowing that their own cannabis flowers are available in pharmacies is a special milestone for physician and co-founder Dr. Adrian Fischer, who is the managing director responsible for cultivation and quality control: "Finally, you can get cannabis from Germany in pharmacies. I am particularly pleased that many patients can be helped with this fine product and that we can improve the supply situation through cultivation in this country. Of course, it would be desirable if we were allowed to produce considerably more. DEMECAN is be able to do that."

From a Berlin startup to Germany's largest cannabis producer.

Since 2017, cannabis has been legally approved as medicine in Germany. In 2019, DEMECAN was the only independent German company to be awarded a contract by the German government for the production of cannabis flowers for medical use. The associated supply contract is valid for the period of four years. Production will take place at the EU-GMP certified production facility near Dresden and in accordance with the high quality standards of pharmaceutical manufacturing.

DEMECAN acquired the 100,000 sqm production site in the summer of 2020. In under 15 months of construction, the building - a former slaughterhouse - was converted and is now the largest indoor cannabis production facility in Europe. 24 cm of reinforced concrete in all walls, steel doors, 150 cameras and a high-tech computer system to control and optimize plant growth, ensure the perfect cultivation of the plants. Thanks to the modular expandable production capacities, DEMECAN can also massively increase the production capacity at short notice to meet the growing demand in Germany.

About DEMECAN

DEMECAN is the only independent German company that covers the entire value chain for medical cannabis - from cultivation to processing and storage to distribution to pharmacies. The company was founded in 2017 by Dr. Adrian Fischer, Dr. Cornelius Maurer and Dr. Constantin von der Groeben with the aim of guaranteeing patients access to medical cannabis in "Made in Germany" quality. In May 2019, DEMECAN was awarded a state contract by the Federal Institute for Drugs and Medical Devices (BfArM) as the only independent German company to cultivate and distribute medical cannabis in Germany. Cultivation and further processing are carried out according to the highest pharmaceutical standards (EU-GMP) at the company's facility near Dresden. As a pharmaceutical wholesaler, DEMECAN works with cannabis producers worldwide and imports medical cannabis that meets its own high quality standards. The DEMECAN Group is a member of the Federal Association of Pharmaceutical Cannabinoid Companies (BPC) and a supporting member of the Association of Pharmacies Supplying Cannabis (VCA e.V.).

Further Information: www.demecan.de
Press contact: press@demecan.de

Growth Opportunity Cannabis Legalization

DEMECAN founder Dr. Maurer joins the supervisory board and hands over operational responsibility to former Merck manager Dr. Goebel

Berlin/Dresden, 09. March 2022 – The imminent legalization of cannabis for recreational purposes opens up new business opportunities for DEMECAN, the only independent German producer of medical cannabis. To seize the opportunities, the company is reorganizing its management and supervisory board. In the future, Dr. Cornelius Maurer will drive strategic topics from the supervisory board, and focus on the legalization of recreational cannabis, German cannabis association work and capital acquisition. With Dr. Philipp Goebel the cannabis producer is gaining further expertise from the pharmaceutical sector and a proven specialist in pharmaceutical sales, marketing and supply chain management to the management board.

DEMECAN is the only independent German cannabis producer supplying patients in Germany with cannabis flowers from its own EU-GMP certified facility near Dresden. As a wholesaler, DEMECAN also imports medicinal cannabis flowers and extracts from abroad. DEMECAN was founded in 2017 by Dr. Cornelius Maurer, Dr. Adrian Fischer and Dr. Constantin von der Groeben. The trio has built the Berlin-based startup into Germany's most successful cannabis producers and cannabis wholesaler.

With the commissioning of Europe's largest indoor production facility for cannabis and the upcoming first cannabis delivery to the Federal Institute for Drugs and Medical Devices (BfArM), the founders are opening a new chapter in the company's history. For founder Dr. Maurer this is the ideal time for a change to the supervisory board and a strategic reorientation. In the future, he will focus on the strategically important topics such as legalization of cannabis for recreational usage, cannabis association work and capital acquisition. At the same time, he will turn to new operational challenge: As founder and managing director, Dr. Cornelius Maurer will lead 420 Venture Capital GmbH from Berlin.

"My understanding as a founder is to get ideas off the ground, create values, and develop a solid foundation for a long-term successful company. DEMECAN is a success story and I am more than proud of the performance, creativity and passionate commitment of our entire team. Five years after its foundation, DEMECAN has established itself as the only independent producer and wholesaler of medical cannabis in Germany and it is the right time for me to fully focus on strategic topics in the future, such as the emerging stimulant market for recreational cannabis, cannabis association work and fundraising ", explains Dr. Cornelius Maurer.

Focus on the growing demand for cannabis in Germany

Dr. Philipp Goebel, an experienced executive for pharmaceutical sales and marketing as well as supply chain management, takes over the operational responsibility as managing director for procurement, product strategy, sales and marketing of DEMECAN. In his previous role at Merck, the world's oldest pharmaceutical company, he was responsible for the business unit Neurology & Immunology. Dr. Goebel's prior sales and marketing experience in oncology and neurology, key application areas of medical cannabis, complements the expertise of the entire management team and ensures a continuation of the rapid growth of DEMECAN.

"The step that Dr. Cornelius Maurer has now taken is not easy for any founder. It is a sign of great strength and leadership quality to hand over the operational responsibility of our company and to focus on strategic topics from now on as a shareholder and supervisory board member. The development of the past five years under Dr. Cornelius Maurer has been tremendous, and DEMECAN is in an ideal position to become the German market leader for medical and recreational cannabis due to our modular expandable production capacities, our focus on continuous research and development of new flower products, the broad supplier base as well as the strong distribution channels. With the help of managing director Dr. Philipp Goebel and his experience in the pharmaceutical and logistic sector, we will take DEMECAN to the next level of development," explains Dr. Constantin von der Groeben, founder and managing director at DEMECAN.

Co-founders Dr. Constantin von der Groeben and Dr. Adrian Fischer as well as Jörg Sellmann will remain operationally active in the company as managing directors.

About DEMECAN

DEMECAN is the only independent German company that covers the entire value chain for medical cannabis - from cultivation to processing and storage to distribution to pharmacies. The company was founded in 2017 by Dr. Adrian Fischer, Dr. Cornelius Maurer and Dr. Constantin von der Groeben with the aim of guaranteeing patients access to medical cannabis in "Made in Germany" quality. In May 2019, DEMECAN was awarded a state contract by the Federal Institute for Drugs and Medical Devices (BfArM) as the only independent German company to cultivate and distribute medical cannabis in Germany. Cultivation and further processing are carried out according to the highest pharmaceutical standards (EU-GMP) at the company's facility near Dresden. As a pharmaceutical wholesaler, DEMECAN works with cannabis producers worldwide and imports medical cannabis that meets its own high quality standards. The DEMECAN Group is a member of the Federal Association of Pharmaceutical Cannabinoid Companies (BPC) and a supporting member of the Association of Pharmacies Supplying Cannabis (VCA e.V.).

Further Information: www.demecan.de
Press contact: press@demecan.de

DEMECAN receives GMP certificate for cannabis production facility

Berlin/Dresden, 25. January 2022 - DEMECAN, the only independent German producer of medicinal cannabis, has been granted a manufacturing license in accordance with §13 AMG (German Medicines Act) and GMP (Good Manufacturing Practice) certification for its production facility near Dresden. The GMP manufacturing license granted by the Saxon state authority allows DEMECAN to produce dried cannabis as medicinal products with immediate effect.

The internationally recognized certification ensures the high quality of medicinal products over the entire manufacturing process. GMP stands for "Good Manufacturing Practice" and means the highest manufacturing standards, which are independently monitored and inspected by pharmaceutical authorities.

Dr. Adrian Fischer, a medical doctor and DEMECAN's managing director, is pleased: "GMP certification is the strictest standard that manufacturers have to meet, as high quality is expected from pharmaceuticals. The fact that we now hold this certificate in our hands is an extraordinary milestone in DEMECAN's young history and an important one for the development of the German Cannabis Center in Saxony. As founder and CEO, I am very grateful for the great team with which we managed to pass the inspection only six weeks after the completion of our building. And we have now fully ramped up production capacity. That's an incredible accomplishment, and we'll celebrate that appropriately as soon as the Covid situation allows."

The way is now clear for the first cannabis flowers "Made in Germany". DEMECAN still plans to deliver the first products to the state cannabis agency and through it to pharmacies in Q1/22. The in-house produced flower will then complement the existing Florestura flower portfolio.

With GMP certification, DEMECAN can now produce its own medicines and test them for efficacy through clinical trials. The research activity is important as there is still prejudice against cannabis in medicine. In order to pave the way for further therapeutic areas and to further reduce the prescription hurdles for patients, further research is therefore needed both nationally and internationally. DEMECAN supports this and plans to start its own study this year.

About DEMECAN
DEMECAN is the only independent German company that covers the entire production chain for medical cannabis - from cultivation, processing, and storage to distribution to pharmacies. The company was founded in 2017 by Dr. Adrian Fischer, Dr. Cornelius Maurer and Dr. Constantin von der Groeben with the aim of guaranteeing patients access to medical cannabis with "Made in Germany" quality. The Federal Institute for Drugs and Medical Devices (BfArM) awarded DEMECAN the contract to grow and process medical cannabis in May 2019. Cultivation and further processing are carried out in accordance with the highest pharmaceutical standards at the facility near Dresden. As a pharmaceutical wholesaler, DEMECAN cooperates with cannabis producers worldwide and imports medical cannabis that meets its own high-quality standards. The DEMECAN Group is a member of the Federal Association of pharmaceutical Cannabinoid Companies (BPC) and a supporting member of the Association of Cannabis Supplying Pharmacies (VCA e.V.).

Further Information: www.demecan.de
Press contact: press@demecan.de

DEMECAN again receives funding in the millions

Berlin/Dresden, 15. April 2021 - DEMECAN, Germany’s only independent producer of medical cannabis, has closed another multi-million Euro financing round. The investment will be used for further growth as well as the expansion of the production facility, located near Dresden, into Europe's most modern facility for the cultivation and processing of medicinal cannabis.

The investment in the upper single-digit million range comes from private and institutional investors, among whom is new investor Futury Fund as well as existing shareholders, including the btov Private Investor Network.

"It is DEMECAN’s mission to guarantee the nationwide supply of high-quality medical cannabis for the benefit of patients in Germany. Therefore, we not only focus on the cultivation of medical cannabis but are also active in the field of R&D to develop new and innovative dosage forms," explains Dr. Adrian Fischer, physician, co-founder, and CEO of DEMECAN.

This financing round is an important step for DEMECAN in its rapid growth trajectory since being selected as a supplier of medical cannabis for the Federal Republic of Germany in 2019. In addition to product development and distribution, strategic objectives include collaborations with research-based pharmaceutical companies and the coordination and strengthening of operational pharmaceutical distribution.

To implement the corporate strategy, the DEMECAN Group intends to establish a subsidiary in the state of Hessen. The immediate proximity to pharmaceutical companies is critical as is cooperation with smaller cannabis companies in the region. The aim is to establish a dedicated medical cannabis research cluster, where knowledge of medical cannabis is combined with experience from large-scale pharmaceutical production. This will further enable DEMECAN to grow and conduct research more rapidly.

"DEMECAN has been able to establish itself early on as a leader in the medical cannabis market and we are convinced that it is positioned to take a leading role in Europe as well," said Benjamin Krahmer, Managing Director of Futury.

About DEMECAN
DEMECAN is the only independent German company that covers the entire production chain for medical cannabis - from cultivation, processing, and storage to distribution to pharmacies. The company was founded in 2017 by Dr. Adrian Fischer, Dr. Cornelius Maurer, and Dr. Constantin von der Groeben to guarantee patients access to medical cannabis with "Made in Germany" quality. The Federal Institute for Drugs and Medical Devices (BfArM) awarded DEMECAN the contract to grow and process medical cannabis in May 2019. Cultivation and further processing are carried out in accordance with the highest pharmaceutical standards at the facility near Dresden. As a pharmaceutical wholesaler, DEMECAN cooperates with cannabis producers worldwide and imports medical cannabis that meets its high-quality standards. The DEMECAN Group is a member of the Federal Association of Pharmaceutical Cannabinoid Companies (BPC) and a supporting member of the Association of Cannabis Supplying Pharmacies (VCA e.V.).

Further Information: www.demecan.de
Press contact: press@demecan.de

DEMECAN: With pioneering spirit and responsibility for patient care.

Berlin/Dresden, 03. March, 2021 - For just under four years, seriously ill patients have been able to obtain medical cannabis on prescription. Tens of thousands of patients with chronic pain, spasticity, anorexia/wasting, nausea and vomiting during chemotherapy already benefit from this additional therapy option. But growing demand exceeds availability, and bureaucratic hurdles make prescribing difficult. Despite this imbalance, patient care must be ensured. DEMECAN, as a German pioneer, is committed to the security of supply and ensuring therapeutic diversity under the highest pharmaceutical quality.

The possibility of prescribing cannabinoids for the therapy of seriously ill people has added an important add-on therapy to the framework of a multimodal therapy approach. In the first half of last year, over 160,000 SHI prescriptions of cannabinoids were recorded. As use increases, so does knowledge about the indications, effects, and side effects, as well as the therapeutic diversity of the products. In addition to the indication of chronic pain, other areas of application include oncology (e.g. tumor pain) and neurological diseases (e.g. epilepsy). Nevertheless, significant underuse of seriously ill patients is to be expected, especially in the field of family medicine. The main reasons are bureaucratic hurdles in the application process and skepticism on the part of physicians and insurances.

Ensure supply

The health policy objective of a quality-assured and demand-oriented supply of patients in Germany with cannabis-based medicinal products primarily provides for the regulated cultivation in Germany. DEMECAN was awarded the contract for the cultivation of medical cannabis by the Federal Institute for Drugs and Medical Devices (BfArM) and has set itself the task of ensuring the nationwide supply of high-quality medical cannabis in "Made in Germany" quality for the benefit of patients. For this purpose, medical cannabis is produced under strictly controlled conditions near Dresden.

From cultivation to further processing and storage to delivery to pharmacies - at DEMECAN everything is covered from a single source - making it the only independent German company that cultivates cannabis for medical purposes in Germany.

Focus on the patient

Only a small proportion of severely ill patients who could benefit from additional add-on therapy are already receiving add-on therapy with cannabis-based medicines today. The total of 3.8 million patients with severe chronic pain alone suggests an undersupply. Also, data from the cannabis companion survey ordered by the federal government indicate that the diagnostic spectrum of medical cannabis is expanding. Imports must be relied upon to meet national supply needs, preferably from companies with existing medical and quality-assured expertise.

For this reason, DEMECAN has entered into a collaboration agreement with Little Green Pharma, a vertically integrated company from Australia specializing in medical cannabis. Little Green Pharma, like DEMECAN, actively promotes educational programs and participates in clinical trials and research projects of medical cannabis.

With the launch of the medical cannabis flower DEMECAN 20:01 Florestura, a THC-rich flower with Sativa dominance, DEMECAN provides high-quality medical cannabis for patient care.

Safe supply

"Securing care, safe care" is the motto of the Pain and Palliative Day of the German Society for Pain Medicine (DGS) taking place in March. The presidium under Dr. Johannes Horlemann is strongly committed to the adequate care of seriously ill patients. Among other things, for the dismantling of bureaucratic hurdles to facilitate access to medication. But also in the evaluation of the evidence situation around the therapeutic variety of the different dosage forms. In this context, flowers represent an important part of the supply alongside extracts and finished medicinal products. In 2021, the practice guideline "Cannabis in Pain Medicine" will therefore be further developed to take into account the improved study situation in the use of all applications of cannabinoids. Therapy with cannabis flowers will be re-evaluated. DEMECAN has also set itself the goal of ensuring therapeutic diversity and will provide further cannabinoids in pharmaceutical quality for the care of patients soon.

About DEMECAN
DEMECAN is the only independent German company that covers the entire production chain for medical cannabis - from cultivation, processing, and storage to distribution to pharmacies. The company was founded in 2017 by Dr. Adrian Fischer, Dr. Cornelius Maurer and Dr. Constantin von der Groeben with the aim of guaranteeing patients access to medical cannabis with "Made in Germany" quality. The Federal Institute for Drugs and Medical Devices (BfArM) awarded DEMECAN the contract to grow and process medical cannabis in May 2019. Cultivation and further processing are carried out in accordance with the highest pharmaceutical standards at the facility near Dresden. As a pharmaceutical wholesaler, DEMECAN cooperates with cannabis producers worldwide and imports medical cannabis that meets its own high-quality standards. The DEMECAN Group is a member of the Federal Association of pharmaceutical Cannabinoid Companies (BPC) and a supporting member of the Association of Cannabis Supplying Pharmacies (VCA e.V.).

Further information: www.demecan.de
Press contact: press@demecan.de